Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class

The company reported open-label, phase 2 data Thursday showing that a co-formulation of Keytruda and anti-TIGIT therapy vibostolimab did not improve progression-free survival compared to chemotherapy alone in patients with metastatic non-small cell lung cancer that had previously been treated with immunotherapy and platinum-doublet chemotherapy.